Interesting: GCase activity at time of diagnosis was lower in #Parkinsons patients who developed dementia within 10 years than in those who did not (p = 0.001). A 0.1 unit reduction in baseline GCase activity was associated with a faster development of PDD n.neurology.org/content/early/…

Congratulations to our team at NKB on the publication of exciting work showing that CSF GCase activity at PD diagnosis is linked to the future risk of dementia. These results could have important implications for #clinicaltrials in #parkinsons n.neurology.org/content/early/…

It is great to be back in person for the annual ParkWest meeting, bringing together some of the people who make the Norwegian ParkWest study possible and hearing about the exciting work coming from this diverse team! #Parkinsons

It was wonderful to welcome Dr Hayley MacDonald from the University of Bergen today and hear about her work on behavioural, neurophysiological and genetic mechanisms of impulse control #Parkinson

(1/2) Breaking news: A large phase 3 trial of ambroxol currently used to treat cough inflammation is to start in early 2023. This world-first trial will aim to establish its potential to slow the progression of Parkinson’s. buff.ly/3Xlu0r6 Van Andel Institute (VAI) Parkinson's UK

A population-based longitudinal study showed that reduced cerebrospinal fluid lysosomal enzyme glucocerebrosidase activity at the time of #PD diagnosis is associated with an increased risk for PD #dementia. Neurology Journal Read 📗: ow.ly/BHfc50Mn84j

Congratulations to Christina Pedersen who gave a great talk about her work on the development of sensitive biomarkers in Parkinson Universitetet i Stavanger

If you’re one of the 4000 people lucky enough to be at #ADPD2023, please come and talk to us today about some of our newest biomarker work, presented by Johannes Lange (#657) and Maria Camila Gonzalez (#348)

Officially in the contest 📸Carla Abdelnour #ADPD2023 AD/PD - Advances in Science & Therapy

Join us for the last session today at #ADPD2023 to hear about NKB‘s work on GCase activity in #Parkinsons

Great to see Jodi Grødem presenting on behalf of NKB on the last day of #ADPD2023

That’s a wrap for #ADPD2023 ! What an amazing congress with so many great people. See you all in Lisbon for #ADPD2024 when we’ll try to remember to take a lab photo with everyone! Congrats to Maria Camila Gonzalez and Jodi Grødem for staying until the very end!

Debate persists: are DLB & PDD distinct phenotypes? 🧠 In a study by Maria Camila Gonzalez in Movement Disorders Clinical Practice, we showed that DLB and PDD patients experienced similar rates of cognitive and motor decline. This is relevant for future clinical trial designs. …mentdisorders.onlinelibrary.wiley.com/doi/abs/10.100…

Neuroinflammation contributes to #neurodegeneration 🧠Here we explored the value of inflammation-related biomarkers in Parkinson’s Disease, dementia with Lewy bodies, and Alzheimer’s disease, and identified disease-specific biomarker panels nn.neurology.org/content/10/4/e…

21 miles, completed it! ✅ A huge thank you to Graeme, Andy, Sean, Steph, Rob and Andy M for taking on this challenge to help #StopThePain for people living with EB. Donate today and help us find treatments for this cruel condition: bit.ly/43hZ6mx 🦋 #GraemeSouness

It was a great day at *Lewy Body UK* to discuss all the advances that are being made in #LewyBodyDementia

We hope you got to catch some of the work at NKB were presenting this week. It’s been great to meet so many people WPC 2026 !

It was incredible to be part of the group of volunteers at #WPC2023

We had a fantastic time meeting the PICC cohort in person. There are some truly exciting projects emerging from this incredible group 🙌 abdn.ac.uk/iahs/research/…

🌟Exceptional reviews for ParkinsonNet Norway at @arendalsuka! 🌟 The future for providing care in #Parkinsons looks promising with our model 🚀 Read more in Dagens Medisin #ParkinsonNetNorway #Arendalsuka #Healthcare dagensmedisin.no/arbeiderpartie…